Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.28 USD
+0.18 (1.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $12.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.28 USD
+0.18 (1.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $12.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for August 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 2.74% and -37.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
Why Enanta Pharmaceuticals (ENTA) Stock Might be a Great Pick
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 58.90% and -9.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
Enanta Pharmaceuticals (ENTA) Q1 Earnings Top Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 10.17% and -11.37%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -22.81% and -8.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
by Zacks Equity Research
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
Enanta Pharmaceuticals (ENTA) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 371.43% and -4.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 322.22% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -14.38% and -4.34%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.